Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Fish and Richardson
Baxter
Cantor Fitzgerald
Covington
Merck
Fuji
Julphar
Chubb
Cerilliant

Generated: August 17, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Bioadhesive progressive hydration tablets
Abstract:A bioadhesive composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process and more importantly may be protected from moisture and the immediate septic environment until after the patient has applied the composition, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the composition is available for absorption (bioavailable).
Inventor(s): Bologna; William J. (Paris, FR), Levine; Howard L. (Oceanside, NY), DeZiegler; Dominque (Paris, FR)
Assignee: Columbia Laboratories, Inc. (Livingston, NJ)
Filing Date:Jun 11, 2001
Application Number:09/877,218
Claims:1. A bioadhesive, controlled and sustained release, progressive hydration pharmaceutical composition comprising: an effective amount of terbutaline, a water insoluble, water-swellable cross-linked polycarboxylic polymer, and a water soluble polymer, wherein said composition is formulated to deliver said terbutaline to the bloodstream of a mammal through a mucosal surface of the mammal.

2. The composition of claim 1, wherein said terbutaline is present in an amount of about 4 mg/per unit dosage of composition.

3. The composition of claim 1, wherein said terbutaline is present in an amount of about 2 mg/per unit dosage of composition.

4. The composition of claim 1, wherein the mucosal surface is the vagina, and said water insoluble, water-swellable cross-linked polycarboxylic polymer is Polycarbophil.

5. The composition of claim 2, wherein the mucosal surface is the vagina, and said water insoluble, water-swellable cross-linked polycarboxylic polymer is Polycarbophil.

6. The composition of claim 3, wherein the mucosal surface is the vagina, and said water insoluble, water-swellable cross-linked polycarboxlic polymer is Polycarbophil.

7. The composition of any one of claims 4, 5, or 6, wherein said water soluble polymer is carbomer 974P, and said composition further comprises lactose, hydroxypropylmethylcellulose, corn starch, talc, silica, and magnesium stearate.

8. A method of delivering to a mammal an effective amount of terbutaline via a controlled and sustained release, progressive hydration bioadbesive pharmaceutical composition through a mucosal surface of the mammal, comprising said terbutaline, a water insoluble, water-swellable cross-linked polycarboxylic polymer, and a water soluble polymer.

9. The method of claim 8, wherein said terbutaline is present in an amount of about 4 mg/per unit dosage of said composition.

10. The method of claim 8, wherein said terbutaline is present in an amount of about 2 mg/per unit dosage of composition.

11. The method of claim 8, wherein the mucosal surface is the vagina, said water insoluble, water-swellable cross-linked polycarboxylic polymer is polycarbophil, said water soluble polymer is carbomer 974P, and said composition further comprises lactose, hydroxypropylmethylcellulose, corn starch, talc, silica, and magnesium stearate.

12. The method of claim 9, wherein the mucosal surface is the vagina, said water insoluble, water-swellable cross-linked polycarboxylic polymer is polycarbophil, said water soluble polymer is carbomer 974P, and said composition further comprises lactose, hydroxypropylmethylcellulose, corn starch, talc, silica, and magnesium stearate.

13. The method of claim 10, wherein the mucosal surface is the vagina, said water insoluble, water-swellable cross-linked polycarboxylic polymer is polycarbophil, said water soluble polymer is carbomer 974P, and said composition further comprises lactose, hydroxypropylmethylcellulose, corn starch, talc, silica, and magnesium stearate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Cerilliant
Farmers Insurance
Colorcon
Queensland Health
Healthtrust
Mallinckrodt
Fish and Richardson
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot